To own TG Therapeutics stock, you need confidence in BRIUMVI's ability to defend and expand its market share in multiple sclerosis. The latest six-year data reinforces BRIUMVI's clinical profile but does not materially impact the short-term catalyst of subcutaneous (subcu) BRIUMVI's Phase 3 trial, or address the company's heaviest risk, reliance on a single revenue driver amid payers' growing preference for self-administered therapies.